Abstract: Sensor-based shaving systems and methods of analyzing a user's shave event are described for determining a unique threshold value of the user. A grooming device comprises a handle having a connecting structure connected to a hair cutting implement. A shave event sensor associated with the grooming device measures a user behavior, which includes collecting a first dataset comprising shave data defining a shave event. The first dataset is transmitted via a communication device and is analyzed to determine baseline behavior data of the user, and a unique threshold value of the user is determined from the baseline behavior data. One or more subsequent datasets, each comprising shave data of one or more corresponding shave events, is compared to the unique threshold value to determine comparison data. An indication is provided, based on the comparison data, to indicate a deviation from the threshold value and to influence the user behavior.

Abstract: Sensor-based shaving systems and methods of analyzing a user's shave event are described for determining a unique threshold value of the user. A grooming device comprises a handle having a connecting structure connected to a hair cutting implement. A shave event sensor associated with the grooming device measures a user behavior, which includes collecting a first dataset comprising shave data defining a shave event. The first dataset is transmitted via a communication device and is analyzed to determine baseline behavior data of the user, and a unique threshold value of the user is determined from the baseline behavior data. One or more subsequent datasets, each comprising shave data of one or more corresponding shave events, is compared to the unique threshold value to determine comparison data. An indication is provided, based on the comparison data, to indicate a deviation from the threshold value and to influence the user behavior.

Abstract: The present invention relates to novel treatments of periodontal disease by administering a suitable formulation of a cyclophilin inhibitor. The present invention further relates to novel pharmaceutical compositions containing said cyclophilin inhibitor compounds.

Abstract: The present invention relates to novel treatments of periodontal disease by administering a suitable formulation of a cyclophilin inhibitor. The present invention further relates to novel pharmaceutical compositions containing said cyclophilin inhibitor compounds.

Abstract: The present invention relates to novel treatments of periodontal disease by administering a suitable formulation of a cyclophilin inhibitor. The present invention further relates to novel pharmaceutical compositions containing said cyclophilin inhibitor compounds.

Abstract: The invention at hand provides hydrolytically degradable ionic copolymers. These ionic copolymerizates are composed of one cyclic ketene acetal A, one anionic or cationic methacrylic acid derivative B, selected from 2-methyl-methacrylate, [2-(2-methyl-1-methylene-allyloxy)]ethanesulfonate, [2-(2-methyl-1-methylene-allyloxy)ethyl]phosphonate or a quaternary amine of the N,N-dimethylaminoethylmethacrylic acid (DMAEMA) and, optionally, a neutral methacrylic acid derivative C. The hydrolytically degradable anionic copolymers according to the present invention are produced by polymerizing the components A, B and C in the presence of a radical initiator under inert gas atmosphere and subsequent purification. All copolymers according to the present invention are hydrolytically degradable. Copolymers comprising a maximum of 40 mol-% of ester groups in the backbone are additionally biodegradable, wherein in the case of cationic copolymers a maximum of 20 mol-% of quaternized DMAEMA is allowed to be available.

Abstract: The present invention provides biocompatible nano-polymer particles which are composed of a biocompatible polymer, a stabilizer and an active agent for the treatment of pulmonary hypertension or erectile dysfunction and which can be used to produce a pharmaceutical preparation for the treatment of pulmonary hypertension or erectile dysfunction. Biocompatible nano-polymer particles of this invention have a diameter ranging from 10 nm to 10 ?m auf, a stabilizing layer thickness between 0 and 50 nm, contain between 0 and 50% of an active agent for the treatment of pulmonary hypertension or erectile dysfunction, are nebulizable and continuously release the active agent over a period of up to 48 hours. Biocompatible nano-polymer particles of this invention can be synthesized for example using the emulsion technique known to the expert with subsequent solvent evaporation or via spray drying.

Abstract: The present invention relates to graft copolymers of polyvinyl sulfonic-co-vinyl alcohol)-g-poly(lactide-co-glycolide) (P(VS-VA)-g-PLGA) with negatively charged electrolyte properties, their method of preparation and their use. These negatively charged graft copolymers are suitable for effective loading and sustained-release of especially positively charged drugs, proteins and peptides, and drug-loaded particles from these grafted co-polymers are especially useful as parenteral or mucosal drug delivery systems for pharmaceutical applications.

Abstract: The invention relates to composite materials comprising polymer nanofibers and polymer nanoparticles, wherein at least one of the two polymer materials is loaded with a substance selected from therapeutic and diagnostic agents. Fibers and nanoparticles can comprise identical or different polymers; the polymer materials are, however, biocompatible in every case. Therapeutic and diagnostic agents can be hydrophilic or lipophilic and the two polymer materials likewise. The at least one polymer material and the substance with which said material is loaded are either both hydrophilic or both lipophilic. The polymer nanoparticles of the composite materials have a diameter of 10 nm to 600 nm. The polymer fibers have diameters of 10 nm to 50 ?m and lengths of 1 ?m to several meters. The invention further relates to a method for producing said composite materials.

Abstract: The invention relates to low molecular weight polyethylenimines, to vectors for inserting nucleic acids into cells which contain low molecular weight polyethylenimines, and to the preparation and use of the low molecular weight polyethylenimine and the vector. The invention relates to a vector for inserting a nucleic acid into a cell, which vector contains a low molecular weight polyethylenimine (LMW PEI) and a nucleic acid, with the LMW PEI having a molecular weight of less than 50,000 Da.

Abstract: A device implantable into a human or animal body comprising a biodegradable polymer which comprises ethylene carbonate units of the formula A -(—C(O)—O—CH2—CH2—O—)-??A having an ethylene carbonate content of 70 to 100 Mol %, an intrinsic viscosity of 0.4 to 4.0 dl/g measured in chloroform at 20° C. at a concentration of 1 g/dl and a glass transition temperature of from 5 to 50° C., degradable by surface erosion which is governed by a non-hydrolytic mechanism.

Abstract: Poly(ethylene carbonate) (PEC) nanoparticles comprising pharmacologically active substances, their production method and their use for sustained release of the pharmacologically active agent after application are described.

Abstract: The invention relates to low molecular weight polyethylenimines, to vectors for inserting nucleic acids into cells which contain low molecular weight polyethylenimines, and to the preparation and use of the low molecular weight polyethylenimine and the vector. The invention relates to a vector for inserting a nucleic acid into a cell, which vector contains a low molecular weight polyethylenimine (LMW PEI) and a nucleic acid, with the LMW PEI having a molecular weight of less than 50,000 Da.

Abstract: The invention at hand provides hydrolytically degradable ionic copolymers. These ionic copolymerizates are composed of one cyclic ketene acetal A, one anionic or cationic methacrylic acid derivative B, selected from 2-methyl-methacrylate, [2-(2-methyl-1-methylene-allyloxy)]ethanesulfonate, [2-(2-methyl-1-methylene-allyloxy)ethyl]phosphonate or a quaternary amine of the N,N-dimethylaminoethylmethacrylic acid (DMAEMA) and, optionally, a neutral methacrylic acid derivative C. The hydrolytically degradable anionic copolymers according to the present invention are produced by polymerizing the components A, B and C in the presence of a radical initiator under inert gas atmosphere and subsequent purification. All copolymers according to the present invention are hydrolytically degradable. Copolymers comprising a maximum of 40 mol-% of ester groups in the backbone are additionally biodegradable, wherein in the case of cationic copolymers a maximum of 20 mol-% of quaternized DMAEMA is allowed to be available.

Abstract: The present invention relates to graft copolymers of polyvinyl sulfonic-co-vinyl alcohol)-g-poly(lactide-co-glycolide) (P(VS-VA)-g-PLGA) with negatively charged electrolyte properties, their method of preparation and their use. These negatively charged graft copolymers are suitable for effective loading and sustained-release of especially positively charged drugs, proteins and peptides, and drug-loaded particles from these grafted co-polymers are especially useful as parenteral or mucosal drug delivery systems for pharmaceutical applications.

Abstract: Microparticles comprising at least one active agent embedded within a biocompatible, biodegradable polymeric matrix, wherein said microparticles are prepared with an ionic liquid.

Abstract: According to one embodiment, the disclosure relates to a dendrimer complex usable for transfection of a cell and including a nucleic acid to be transfected non-covalently bound to a triazine dendrimer vector. According to another embodiment, the disclosure provides a method of transfecting a cell by contacting the cell with a dendrimer complex as described above. After the contact, the dendrimer complex enters the cell. According to a third embodiment, the disclosure relates to a method of making a triazine dendrimer complex for cell transfection by covalently bonding a series of triazine monomers to a central monomer through a series of reactions to form a triazine dendrimer, then non-covalently bonding a nucleic acid to the dendrimer to form a triazine dendrimer complex operable to transfect a cell.

Abstract: The present invention related to a non-viral vector system for the delivery of nucleic acids which is modified on the basis of polyethylene imine (PEI) with polyethylene glycol (PEG) and which contains a peptide sequence with PTD/CPP-functionality. This vector system is used as gene transfer system for the epithelial cells of the bronchial tubes and alveoli of the lung. The system is highly stable, protects the DNA in the pulmonary environment, has a low zeta-potential and a low aggregation tendency in a medium with a high ionic strength. Furthermore, it is characterized by a low in vitro and in vivo cytotoxicity and allows for a very high transfection efficiency. The vector system according to the present invention is used for a transfection by inhalation in local pulmonary therapy.

Abstract: The invention relates to cationic block copolymers of formula A(-X-B)n, wherein A represents a hydrophilic polymer, B represents polyethyleneimine (PEI), X represents a bridge, n represents 1-200. The invention also relates to methods for producing the inventive cationic block polymers and to their use e.g. as a tenside and for complexing nucleic acids.

Abstract: A device implantable into a human or animal body comprising a biodegradable polymer which comprises ethylene carbonate units of the formula A —(—C(O)—O—CH2—CH2—O—)—??A having an ethylene carbonate content of 70 to 100 Mol %, an intrinsic viscosity of 0.4 to 4.0 dl/g measured in chloroform at 20° C. at a concentration of 1 g/dl and a glass transition temperature of from 5 to 50° C., degradable by surface erosion which is governed by a non-hydrolytic mechanism.